Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 11, Pages 2366-2371
Publisher
American Society of Hematology
Online
2020-05-28
DOI
10.1182/bloodadvances.2019000972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
- (2018) Joseph H. Schafer et al. ANNALS OF PHARMACOTHERAPY
- Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States
- (2018) Konstantinos C. Siontis et al. CIRCULATION
- Safety analysis of apixaban versus warfarin in patients with advanced kidney disease
- (2018) Michael Bowie et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis
- (2018) Ronpichai Chokesuwattanaskul et al. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
- Antithrombotic Therapy for Atrial Fibrillation
- (2018) Gregory Y.H. Lip et al. CHEST
- Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
- (2017) Thomas A. Mavrakanas et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
- (2017) Brooke E. Stanton et al. PHARMACOTHERAPY
- Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens
- (2017) Javier Trujillo-Santos et al. THROMBOSIS AND HAEMOSTASIS
- Antithrombotic Therapy for VTE Disease
- (2016) Clive Kearon et al. CHEST
- Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban
- (2016) Francesco Pelliccia et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
- (2016) Benjamin A. Steinberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Meta-Analysis on Risk of Bleeding With Apixaban in Patients With Renal Impairment
- (2015) Ranjan Pathak et al. AMERICAN JOURNAL OF CARDIOLOGY
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
- (2015) Xiaoli Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
- (2015) Ming Chang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2014) Craig T. January et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Haemostasis in chronic kidney disease
- (2013) Jens Lutz et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism
- (2013) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials
- (2011) Roxana Mehran et al. CIRCULATION
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease
- (2008) H. Reinecke et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started